DelveInsight’s “Acute Bacterial Skin and Skin Structure Infections Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Acute Bacterial Skin and Skin Structure Infections, historical and forecasted epidemiology as well as the Acute Bacterial Skin and Skin Structure Infections market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock key insights into the ABSSSI Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ ABSSSI Market Size

 

Key Takeaways from the Acute Bacterial Skin and Skin Structure Infections Market Report

• In November 2024:- MicuRx- The purpose of this study is to determine whether MRX-I is as safe and effective as Linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections
• The highest rate of MRSA hospitalization was among the elderly—360.8 MRSA stays per 100,000 patients over 65 years of age which was more than three times higher for any other age group, 114.7 stays for infants, 19.2 for 1- to 17-year-olds, 58.1 for 18- to 44-year-olds, and 111.5 for 45- to 64-year-olds per 100,000.
• As per secondary analysis, ABSSSI accounted for almost 870,000 hospital admissions in the United States in 2004 which represents an increase of almost 30% in the incidence of this diagnosis over a 4-year period.
• Among nearly 5 million adult ABSSSI hospital admission, with admissions increasing 17.3% from 2005-2011. ABSSSI patients were primarily male (50.8%), white (60.3%), mean age 55.7 years.
• According to DelveInsight’s analysis, the incidence of ABSSSI Infection is higher in men than women.
• As per analysis, the microorganisms isolated most frequently from SSTIs were Staphylococcus aureus (29.2%), Pseudomonas aeruginosa (11.9%), E. coli (8.9%) and Enterococcus faecalis (7.4%).
• The leading Acute Bacterial Skin and Skin Structure Infections Companies such as Melinta Therapeutics, LLC, Merck, Pfizer, Allergan, Paratek Pharmaceuticals, Cumberland Pharmaceuticals, Teva Pharmaceuticals, and others.
• Promising Acute Bacterial Skin and Skin Structure Infections Therapies such as Contezolid acefosamil, Rifaquizinone (TNP-2092), and others.

 

Stay ahead in the competitive landscape of the ABSSSI Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ ABSSSI Treatment Market Size

 

Acute Bacterial Skin and Skin Structure Infections Epidemiology Segmentation in the 7MM

• Total Incident Cases of ABSSSI community/hospital
• Acute Bacterial Skin and Skin Structure Infections Age-specific Incident Cases
• Acute Bacterial Skin and Skin Structure Infections Gender-specific Incident Cases
• Acute Bacterial Skin and Skin Structure Infections Pathogen-specific Incident Cases

 

Download the report to understand which factors are driving ABSSSI epidemiology trends @ ABSSSI Prevalence

 

ABSSSI Marketed Drugs

• DALVANCE (dalbavancin) : ABBVIE /Durata Therapeutics

DALVANCE (dalbavancin), developed by Durata Therapeutics, represents a groundbreaking therapy addressing the root cause of ABSSSI. Approved by the FDA in May 2014, DALVANCE is an intravenous long-acting lipoglycopeptide antibiotic. Its mechanism of action involves targeting cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of lipid II, a key precursor in this process. Effective against a broad spectrum of Gram-positive bacteria, including MRSA and Streptococcus pyogenes, DALVANCE exhibits bactericidal activity.

 

• ORBACTIV: Melinta Therapeutics

ORBACTIV, a product of The Medicines Company (now part of Melinta Therapeutics), represents a significant breakthrough in ABSSSI treatment. FDA-approved, it offers a novel approach to combating Gram-positive bacterial infections by inhibiting bacterial cell wall synthesis, particularly through binding to the peptidoglycan precursor lipid II. With demonstrated efficacy against various Gram-positive pathogens, including MRSA, ORBACTIV stands out for its unique pharmacokinetic profile, enabling once-daily dosing. This convenience not only simplifies treatment regimens but also holds the potential to enhance patient compliance and improve clinical outcomes in ABSSSI management.

 

Emerging ABSSSI Drugs

• MRX-4: MicuRx

MRX-4 is an injectable new oxazolidinone antibacterial agent, for the treatment of multidrug-resistant (MDR) which exhibits potent activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and penicillin-resistant Streptococcus pneumoniae (PRSP). In September 2018, the US FDA granted qualified infectious disease product status (QIDP) and fast track designation to contezolid acefosamil for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Currenty, the drug is in Phase III of clinical development.

 

• ZEVTERA (ceftobiprole): Basilea Pharmaceutica

ZEVTERA, developed by Basilea Pharmaceutica, is an intravenous cephalosporin antibiotic with rapid bactericidal activity against a broad spectrum of bacteria, including MSSA, MRSA, and susceptible Pseudomonas spp. It is currently approved for the treatment of hospital-acquired pneumonia. In August 2019, positive topline results from the TARGET study were reported, followed by similarly favorable outcomes from the ERADICATE study in June 2022. Subsequently, in April 2024, the US FDA granted approval for the New Drug Application (NDA) of ceftobiprole. This approval encompasses treatment indications for Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSI), as well as community-acquired bacterial pneumonia (CABP).

 

Discover the future of ABSSSI Treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ ABSSSI Market Drivers and Barriers

 

Acute Bacterial Skin and Skin Structure Infections Treatment Market

ABSSSI treatment aims to alleviate symptoms, enhance quality of life, halt disease progression, and prevent recurrence. Initial management, per IDSA guidelines, often involves oral antibiotics effective against streptococci for typical cellulitis cases. However, the prevalence of MRSA has led to a reevaluation of treatment strategies. Major treatment options for mild cases of non-purulent infections include penicillin, amoxicillin, amoxicillin-clavulanate, dicloxacillin, cephalexin, and clindamycin.

 

Acute Bacterial Skin and Skin Structure Infections Drugs Market Landscape

The Acute Bacterial Skin and Skin Structure Infections drugs market for treatments targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI) is xperiencing notable growth, driven by the increasing incidence of these infections and the rising prevalence of antibiotic-resistant bacteria. Innovations in antibiotic therapies, including novel agents and combination therapies, are expanding treatment options and fueling market expansion. Additionally, the growing focus on personalized medicine and rapid diagnostic tools is enhancing the management of ABSSSI. Increased investment in research and development by pharmaceutical companies and the expanding market for advanced healthcare solutions contribute to the sector’s robust growth. As healthcare systems grapple with the challenges of resistant infections, the demand for effective ABSSSI treatments is expected to continue rising.

 

Explore the dynamics of the ABSSSI Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ ABSSSI Ongoing Clinical Trials Analysis

Scope of the Acute Bacterial Skin and Skin Structure Infections Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Acute Bacterial Skin and Skin Structure Infections Companies- Melinta Therapeutics, LLC, Merck, Pfizer, Allergan, Paratek Pharmaceuticals, Cumberland Pharmaceuticals, Teva Pharmaceuticals, and others.
• Acute Bacterial Skin and Skin Structure Infections Therapies- Contezolid acefosamil, Rifaquizinone (TNP-2092), and others.
• Acute Bacterial Skin and Skin Structure Infections Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Acute Bacterial Skin and Skin Structure Infections Unmet Needs, KOL’s views, Analyst’s views, Acute Bacterial Skin and Skin Structure Infections Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. Report Introduction

3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market Overview at a Glance

4. Epidemiology and Market Methodology

5. Executive Summary of ABSSSI

6. Key Event

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Therapies

11. Emerging Therapies

12. ABSSSI: Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. Bibliography

19. Acronyms and Abbreviations

20. Disclaimer

21. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/lactose-intolerance-market